[Application for academic multicenter studies at German ethical review boards]

Area of Science:

• Clinical Research
• Medical Ethics
• Hematology

Context:

• Clinical trials require Institutional Review Board (IRB) approval before commencement.
• Germany's decentralized IRB system involves numerous independent boards for multicenter studies.
• Rare disease trials often necessitate broad participation across many centers.

Purpose:

• To outline the complexities of the IRB application process for academic multicenter trials in malignant hematologic diseases.
• To identify challenges within the current German IRB application system.
• To propose potential improvements for streamlining IRB submissions.

Summary:

• The application procedure for academic multicenter trials, particularly in rare malignant hematologic diseases, is frequently hindered by bureaucratic complexities.
• Multiple independent IRBs in Germany can manage different sites within a single multicenter study.
• The extensive site participation required for rare disease trials exacerbates these application challenges.

Impact:

• Streamlining IRB application processes can accelerate the initiation of crucial clinical trials for rare hematologic malignancies.
• Improved efficiency in IRB submissions may reduce the administrative burden on researchers.
• Facilitating multicenter rare disease research can lead to faster development of novel therapies and better patient outcomes.